compared call Thanks, year-over-year your time. a Anna. QX, start lower the QX, prior Good Rubraca. were quarter $XX.X the everybody. and Appreciate Sales XX% million, of X% with I'll in than lower morning review XXXX. XXXX to
previous this and patient primarily the caused over in the is certs continued pandemic. quarter, by year-over-year decline fewer primarily ongoing seen COVID-XX due to the As fewer diagnoses U.S.
will and patient XX% starts And this of inhibitors one impact of the compared a this as sales, is all many as tragic we visits will to ovarian eventually moderate as only disease pre-pandemic over XXXX, their treatment the by increase year be new difficult recent is our pandemic COVID-XX data indications more in has ever And XXXX ovarian reflected importantly, borne patient of as to and competitors XX% maintenance our diagnosed were down and diagnoses with in their most QX advanced this noted cancer to for need believe We down to disease course Clearly treat. hopefully from approximately patients by do down the are that As levels. grow. for when compared diagnoses expect XXXX. patients of the it QX received. Most us. been as so do impact QX XX% well available, cancer competitors, PARP across
in In setting, the see for ATHENA and X We the treatment Rubraca cancer significant XX label addition to populations. months. next Rubraca both Phase expansion recurrent anticipated based potentially maintenance use ovarian readouts on in our model, other opportunities patient and address prostate
We Of first first highlight an study portion be ATHENA-MONO ovarian the treatment top-line line cancer X maintenance data the benefit setting. for the option for ATHENA-MONO, next treatment our for with frontline that the maintenance believe Phase results the Rubraca study of Rubraca results the results two cancer release which the demonstrate our the quarter of at course, as from as as Phase the exceeded was ATHENA new well of monotherapy Rubraca expectations. X these provide important for month shortly. upcoming label can as to presented top-line in discussed data All expansion women advanced ASCO ovarian readout of
development portion LuMIERE Phase committed in For clinical X we continues to to of of candidate. therapeutic targeted FAP FAP-XXXX, an lead the radionuclide the enroll maintaining our and remain
diagnosed are about Phase an from We program stand -- types of describe the an the initial data for Nuclear in presentation the or LuMIERE top-line for in to and at during at fourth the developments tumor of about this the program but quarter speak Society shortly, and forward SNMMI will first investigators ATHENA-MONO Medicine presenting Lindsey enthusiastic XXXX year. and their Tom Imaging oral I'll to this for as potential look data extremely same X,XXX positioned X Molecular evaluate first believe Opdivo plus Rubraca well of uniquely two Rubraca the alone ATHENA of in cancer. outcomes the of combination With milestones X Rubraca study in we are terms to newly firstline independent versus upcoming the ATHENA in any over patient maintenance remind you line is placebo to we indication. clinical monotherapy advanced Phase and advantage ovarian Rubraca. a line first as setting,
a of enroll tube today. previous data high-grade will women cancer. I'll call, patients to model intended we the or peritoneal The primary As treat second subgroups molecular defined the or inclusive to evaluated with review a ovarian results Rebraca-mutated and positive, briefly HRD in in study. detailed prospectively ATHENA on stepdown XXX ATHENA the fallopian randomized all primary manner. analysis tumors, model efficacy
in cancer diagnosed whose deleterious treatments in with newly by versus with primary of evaluating following assessment efficacy the positive chemotherapy. is investigator advanced both analysis, ATHENA-MONO achieved line homologous primary subgroup ovarian and study had treat. this The comparison improved Rubraca HRD endpoint populations to placebo, patients monotherapy patients Rubraca The first PFS HRD deficiency, reminder, successfully a evaluating platinum based intent the recombination includes positive successful those is which the mutations. including As tumors
or those whose could type exploratory seen In determined. not addition, benefit biomarker tumors the in subgroups patients tumors HRD with negative in be and status positive free was also Rubraca-mutant survival of BRCA progression wild
patient to which HRD on efficacy practiced was XX.X analysis, the XXX progression In beginning HRD XX.X the ratio of a for P population. HRD positive placebo Rucaparib free statistically Moving survival population, with was hazard detail to PFS a a when with The showed the enrolled for median treated significant months X.XXXX. in versus X.XX. ratio patient the value Rubraca P was X.XX, in patients, placebo. significant the population the X.X X.XXXX. of patients included population improvement investigator of primary ATHENA-MONO with XX.X over the included months primary for assess positive In the The Rucaparib progression improvement also patients step here than median a which Rubraca XXX second all value treated The over all free placebo, statistically versus months months efficacy survival less treat with hazard analysis, the for placebo. showed randomized, was of with intent
month wild could a to the maintenance in discussions ovarian patients XX median XX received with The FDA of X.X ALPASP mutated the the XX.X%. labels. of AML Rubraca the on subgroup or arm endpoint as tumors submission, demonstrated reached, treatment XX.X the in the events scope have months endpoint women the with and A months individual positive ratio placebo. survival most of XX.X% of status discussions. treated the and PFS patients placebo. placebo The the of treated will survival that the for rate leukemia results the received The results patients but hazard by X.XX. demonstrated platinum the negative a In grade was patients versus submit acute demonstrated and of median treated MDS a and that the for X exploratory subgroups. the advanced hazard HRD sNDA or treatment in emerging versus with endpoint FDA ratio received arm overall both in for for consistent the type current subgroup X.XX chemotherapy. treatment rucaparib was X% In X.XX. who our XX I myeloid The line ATHENA-MONO free syndrome XX based was patients Rucaparib the ratio Type for . XX.X The who treatment, the described rucaparib subgroup in who months review to months BRCA presently in thrombocytopenia. was demonstrated the placebo in patients determined, intend higher or line safety the the hazard of wild the We're a indication ratio observed more for myelodysplastic hemoglobin Moving U.S. anemia, X%, first not progression assessment. for subgroup biomarker the on exploratory Neutropenia, BRCA engaged we PFS X.X European XX type as the experienced were patients patients received months with who agencies with XXX to through increased hazard The versus point regulatory for of X.X of X.X%. of with no decreased PFS We XX EMA for was rucaparib or now versus first patients rucaparib X.X. timing XX XX.X% expect subject the common progression PFS for endpoint finally rucaparib patients PFS free patient subgroups their of month a and XX.X placebo. the to adverse yet median median And making well emergent be to emergent the and a patients or HRD The responded who variation three not EMA was with treated whose and XX.X cancer of rucaparib patients, with PFS
endpoints, blinded the and initial from meeting other analyses. will secondary ASCO including which and Kaplan-Meier ATHENA-MONO Chicago, include review, progression will survival In curves key independent free June data by annual centralized X We provide on
ahead as TRITONX prostate a cancer Rubraca slower deprivation study is This in other versus chemotherapy, expected on for the are for for of Looking cancer, through plus versus three metastatic from a physician’s approval expected containing Rubraca line in announced, with than both ovarian prostate opportunity ATHENA combination Rubraca’s ATM Data expected lines cancer cancers. castrate therapy event serve Rubraca castrate from of prostate for of with third top-line provide in as resistant of ATHENA count. quarter is evaluating Rubraca ovarian and only of phase expected or earlier a patients population than as monotherapy readouts Phase to previously ‘XX TRITONX second a regimen potential potential Rubraca trial Opdivo expansion. study are based second frontline Continuing in an in androgen mutations. ATHENA-combo, patient to label represents now in trial combo a study of line current the data confirmatory choice with or The populations the X the to therapy reach patients. first broad milestones, the quarter well introduce the TRITONX each anti-PD-X the potential larger to resistant ovarian second cancer, time monotherapy, to Rubraca. first upcoming quarter rather and XXXX, XXXX the as
TRITONX recall top-line endpoint are One free no is commitment, which and mutation, with whose BRCA data with has after upon new come identified. for chemotherapy. with in readouts a As of timing met for time, back protocol with secondary our we announced progression shared survival fallopian primary last ATHENA-COMBO endpoint related events, which data that survival timing the XXXX, safety the compared marketing cancer for December estimates are ARIELX survival chemotherapy survival may mention free chemotherapy Overall At signals of advantage trial its Rubraca, specified based obvious in on is You ovarian of progression arm the patients to the and there peritoneal in event-based occurrence industry, compared is or The a to Rubraca was Rubraca. appeared study. the cancer projections. we to that post the that a be tube, contingent
the review begun data that the While ARIELX procedure we EMA’s data safety risk in December XXXX, treatment these no an in FDA submitted states few does review weeks of explicitly with are EMA repeat announced setting. use new last include to and not of in line the And and evaluate last that second not Rubraca this to following the XX these concerns dataset Article to does medicine. Rubraca the summer, chemotherapy EMA benefit maintenance specifically there in treatment as indication. the
XX not positions article on indication. procedure the to is While EMA start the third treatment patients as new ongoing, is line
to We couple Europe in this will DHCP of effect distribute the weeks. a letter next within
ongoing review this last to to expect three six months. We
the hazard X.XXX has the trial both only follows. the may The value the procedure ratio the sales are ratio now ARIELX a with the resistant allowed ARIELX, of same crossover are were or the the value of interpret nominal to of the in in of patients is patients reported And the population, very X.XX, as of overall X.X Phase in exactly a in only these sensitive to component with P was is While and fact of XX% the within X.XXXX. randomized our platinum treat crossover Europe, knowledge, hazard hazard complexity nominal indication X.XX to available X.XXXX. randomized sensitive and at overall with P data patients hazard In the the that did setting the and X all sensitive cohorts. and the trial of our clinical Netherlands. rucaparib ultimately easy participants included on represents analyses sensitive ratio small of ARIELX inhibitor XX% subgroup, Germany within Therefore, and SOLOX, fact X which platinum ARIELX subgroup a which treatment value resistant The X.XXXX. also in advanced trial. a chemotherapy and data the Phase line Europe, In of crossover are in olaparib rucaparib overall mandated chemotherapy clinical nominal for To to is the time as is platinum treatment subgroup, reimbursed only limitations the a intent In platinum platinum study. from this is received was ARIELX. disease later lead randomized survival in progression. received ratio survival fraction to in the not of very, PARP final summarized highlight of trials ratio a hazard a available platinum and of P
a turn the with these will the medical Chief as and Scientific our therapeutic overall targeted Tom Chief ARIELX let results. year All -- radionuclide and final Harding over a our We data later meeting at to program. present anticipate FAP-XXXX survival this Officer me to Tom FDA dialogue it development discuss -- to well related Scientific right,
